lilly glp 1 weight loss The battle over the trillion-dollar weight-loss bonanza FDA approves Foundayo, an oral

and Michael Holers, MD, answer audience questions at the end of the 2026 Transforming Healthcare event

Accuracy and reliability of self-reported weight and height in the sister study

There are no guarantees that orforglipron will be approved or make it to market on the anticipated timeline

Clinical data show that a significant share of patients lose less than 5 percent of their body weight on GLP-1 therapy

Nutrition standards for away-from-home foods

At present, tirzepatide is the leading GLP-1/GIP dual agonist and has been approved for marketing in many countries, including the US, Europe and Japan, for the treatment of T2D